Bridging Science and Clinical Practice in Myositis

Autoimmune myopathies, including dermatomyositis and immune-mediated necrotizing myopathy (IMNM), remain complex multifaceted conditions that pose ongoing challenges in diagnosis, treatment selection, and long-term management. As the evidence base continues to expand, clinicians are increasingly tasked with translating clinical trial findings and real-world data into practical treatment strategies.

This symposium will feature expert faculty who will (i) review the latest clinical evidence supporting immunoglobulin therapy in autoimmune myopathies, (ii) highlight emerging developments in the field, and (iii) discuss how these insights can be applied in everyday practice.

Presentations will include information from recent and ongoing clinical studies, complemented by illustrative patient cases involving dermatomyositis or IMNM. This approach aims to provide a foundation for interactive dialogue with the audience and support informed decision-making in routine clinical care.

Agenda

Wednesday, 25 March 2026
13.30 - 14:15
Auditorium VI & VII

For healthcare professionals only.
This session is not included in main meeting CME/CPD credit

Speakers